Related Experiment Video
Updated: Jul 13, 2026
Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT
Published on: January 22, 2018
PDGFR-alpha as a potential therapeutic target in uterine sarcomas
S F Adams1, J A Hickson, J Y Hutto
1Department of Obstetrics and Gynecology, University of Chicago, Chicago, IL, USA.
Objective:
Uterine sarcomas are a heterogeneous group of tumors with a propensity for metastasis and resistance to conventional therapy. Recent success in the treatment of other solid tumors with the targeted tyrosine kinase inhibitor imatinib mesylate offers new avenues for investigation. The primary target of imatinib is c-kit, but the drug also inhibits PDGFR-alpha and PDGFR-beta. Given the lack of identified molecular targets in endometrial stromal sarcomas, leiomyosarcomas, and carcinosarcomas, the purpose of this study was to determine the protein expression of c-kit, PDGFR-alpha, and PDGFR-beta in these tumors as a preliminary step to determining their susceptibility to directed therapy. A secondary goal was to identify specific gene mutations that might be associated with activation of these proteins in uterine sarcomas.
Methods:
Archived tissue from 42 cases of uterine sarcomas was stained for c-kit, PDGFR-alpha, and PDGFR-beta using immunohistochemistry. Laser-capture microdissected samples of uterine carcinosarcomas, or homogeneous areas of leiomyosarcomas or endometrial stromal sarcomas, were subjected to genetic analysis of PDGFR-alpha exons 12 and 18.
Results:
The majority (38/42, 90%) of uterine sarcomas lacked c-kit expression and 90% (38/42) demonstrated negative or weak staining for PDGFR-beta. In contrast, 70% (30/42) of cases had strong staining for PDGFR-alpha in the tumor but not in normal myometrium or endometrium. Sequencing results revealed no mutations in exons 12 or 18 of PDGFR-alpha.
Conclusion:
c-kit and PDGFR-beta are unlikely to represent primary treatment targets in uterine sarcomas. The strong expression of PDGFR-alpha in uterine sarcoma specimens suggests a role for this receptor in tumor development, although its potential as a therapeutic target requires further investigation.
Insights
Uterine sarcomas show low expression of c-kit and PDGFR-beta, making them unlikely treatment targets. However, strong PDGFR-alpha expression suggests its potential role in tumor development, warranting further investigation for targeted therapies.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Uterine sarcomas are aggressive cancers with limited treatment options.
- Targeted therapies like imatinib mesylate show promise in other solid tumors.
- Imatinib targets tyrosine kinases including c-kit, PDGFR-alpha, and PDGFR-beta.
Purpose of the Study:
- To investigate the protein expression of c-kit, PDGFR-alpha, and PDGFR-beta in uterine sarcomas.
- To identify potential molecular targets for directed therapy in endometrial stromal sarcomas, leiomyosarcomas, and carcinosarcomas.
- To detect gene mutations associated with these protein targets in uterine sarcomas.
Main Methods:
- Immunohistochemistry was used to assess protein expression in 42 uterine sarcoma tissue samples.
- Laser-capture microdissection isolated specific tumor cells for genetic analysis.
- Genetic analysis focused on exons 12 and 18 of the PDGFR-alpha gene.
Main Results:
- 90% of uterine sarcomas lacked c-kit expression.
- 90% showed negative or weak PDGFR-beta staining.
- 70% exhibited strong PDGFR-alpha expression in tumor tissue, but not normal tissue.
- No mutations were found in PDGFR-alpha exons 12 or 18.
Conclusions:
- c-kit and PDGFR-beta are unlikely therapeutic targets for uterine sarcomas.
- Strong PDGFR-alpha expression suggests a role in uterine sarcoma development.
- Further research is needed to explore PDGFR-alpha as a potential therapeutic target.
Related Concept Videos
02:38Mitogens and the Cell Cycle
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...